Design, Synthesis, Molecular Docking, Invitro Anticancer and Antibacterial Evaluation of Novel Pyrazole Linked with Quinazoline Scaffolds

Abstract

A novel series of compounds are synthesized N-(2-methyl-4-oxoquinazolin-3(4H)-yl)-3-oxo-3-(3,5-diphenyl-2H-pyrazol-1(5 H)-yl) propenamide (3a-l). All the synthesized compounds are characterized by different spectral tools 1HNMR, IR,13CNMR, and MASS. It was screened as in vitro anticancer and antibacterial activity. Among the synthesized compounds 3d and 3e exhibit potent against three cancer cell-line MCF7, PC-3, HT-29. IC50(µM) 3d (16.52, 13.24, 10.15 μg/ml) 3e (17.28, 15.26, 12.33 μg/ml) with standard drugs doxorubicin (15.29, 12.26, 9.06 μg/ml) and 5-fluorouracil (16.15, 13.73, 10.25 μg/ml). Antibacterial activity 3d, 3e, 3j, 3k scaffolds exhibit a promising activity with the standard drug ciprofloxacin. Insilico molecular docking is examined, Its predicted a good binding affinity against with 5C5S, 6XXN, 3K46 proteins.